Form 4: RA Capital Management Reports Director Equity Compensation at Acumen Pharmaceuticals

RA Capital Management, a significant shareholder and director of Acumen Pharmaceuticals, reported the grant of restricted stock units and stock options to director Laura Stoppel as part of the company's non-employee director compensation policy.

Summary

• RA Capital Management, L.P., along with related entities and individuals (RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Peter Kolchinsky, and Rajeev Shah), filed a Form 4 regarding transactions in Acumen Pharmaceuticals, Inc. (ABOS).
• The filing reports the grant of 12,800 Restricted Stock Units (RSUs) and options to purchase 19,500 shares of Common Stock to Laura Stoppel, a director of Acumen Pharmaceuticals and a Principal of RA Capital Management, L.P.
• The RSUs were granted at a price of $0 per share, while the stock options have an exercise price of $1.07 per share.
• Both the RSUs and stock options are scheduled to vest in full on the earlier of June 4, 2026, or Acumen Pharmaceuticals' 2026 annual stockholder meeting, contingent upon Dr. Stoppel's continuous service as a director.
• RA Capital Management, L.P. and its related entities disclaim beneficial ownership of these specific RSU and option grants, as Dr. Stoppel holds them for the benefit of RA Capital Healthcare Fund LP and RA Capital Nexus Fund II, L.P., with proceeds offsetting advisory fees.
• As of the reporting date, RA Capital Healthcare Fund LP directly holds 13,043,179 shares of Common Stock, RA Capital Nexus Fund II, L.P. directly holds 1,300,034 shares, and a separately managed account holds 588,850 shares.

Sentiment

Score: 5

Explanation: The document reports a routine compensation grant to a non-employee director, which is a neutral event in terms of company performance or strategic shifts. It reflects standard corporate governance and compensation practices.

Positives

• The grant of equity compensation to a non-employee director aligns the director's interests with those of the company's shareholders, promoting long-term value creation.
• The compensation structure is a standard practice for publicly traded companies to attract and retain qualified board members.

Risks

• The vesting of RSUs and options will result in a minor dilution of existing shareholder equity when the shares are issued or exercised.

Future Outlook

The document primarily reports a past transaction (grant date) and specifies future vesting dates for the granted equity, which are contingent on continued service. No broader forward-looking statements or guidance on company performance are provided.

Management Comments

• "RA Capital Management, L.P. (the 'Adviser') is the investment manager for RA Capital Healthcare Fund, L.P. (the 'Fund'), RA Capital Nexus Fund II, L.P. (the 'Nexus Fund II') and a separately managed account (the 'Account'). The general partner of the Adviser is RA Capital Management GP, LLC (the 'Adviser GP'), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."
• "Under Dr. Stoppel's arrangement with the Adviser, Dr. Stoppel holds the RSU and the option for the benefit of the Fund and the Nexus Fund II. Dr. Stoppel is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement of the RSU, as applicable, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the RSU, the option and underlying common stock."

Industry Context

The granting of equity compensation, such as restricted stock units and stock options, to non-employee directors is a common and widely accepted practice across various industries, particularly in the biotechnology and pharmaceutical sectors where long-term value creation and alignment of interests are crucial.

Comparison to Industry Standards

• The use of RSUs and stock options for non-employee director compensation is a standard practice observed across publicly traded companies, including peers in the biotechnology sector.
• The vesting schedule tied to continued service is typical for such grants, ensuring retention and ongoing commitment from board members.

Corporate Governance

Related Party Transactions

• The grants to Laura Stoppel, a director of Acumen Pharmaceuticals and a Principal of RA Capital Management, L.P. (a 10% owner and director), constitute a related party transaction.
• The arrangement where Dr. Stoppel holds the equity for the benefit of RA Capital funds and is obligated to turn over net proceeds to offset advisory fees further details the related party nature of the transaction.

Stakeholder Impact

• Shareholders: Experience minor potential future dilution from the issuance of shares upon vesting/exercise of the granted equity, but benefit from the alignment of director incentives with long-term company performance.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.
• RA Capital Management, L.P. and its Funds: Benefit from the arrangement where proceeds from Dr. Stoppel's grants offset advisory fees owed by the funds.

Next Steps

• The granted RSUs and stock options will vest on the earlier of June 4, 2026, or the Issuer's 2026 annual stockholder meeting, subject to Dr. Stoppel's continuous service.

Key Dates

Recommendation

Keywords

Acumen Pharmaceuticals, ABOS, RA Capital Management, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Director Compensation, Beneficial Ownership, Equity Grant